Published in Expert Rev Vaccines on October 04, 2013
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood (2014) 1.92
HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res (2014) 1.37
Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest (2015) 1.13
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics (2015) 1.08
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology (2014) 0.90
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside. Br J Cancer (2014) 0.87
Peptide-based vaccines for cancer therapy. Hum Vaccin Immunother (2014) 0.77
Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother (2016) 0.76
Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines (Basel) (2015) 0.75
Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. Mol Cell Proteomics (2016) 0.75
Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. PLoS One (2016) 0.75
HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. Oncoimmunology (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res (1960) 5.31
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Peptides naturally presented by MHC class I molecules. Annu Rev Immunol (1993) 4.66
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Current enigmas in cancer research. Harvey Lect (1973) 3.91
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov (2012) 2.39
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
Human tumor antigens for cancer vaccine development. Immunol Rev (1999) 1.76
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol (2013) 1.50
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26
Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A (2005) 1.24
Towards patient-specific tumor antigen selection for vaccination. Immunol Rev (2002) 1.22
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother (2004) 1.09
The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron (2012) 0.98
Biochemical large-scale identification of MHC class I ligands. Methods Mol Biol (2013) 0.98
Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules. Semin Immunol (1999) 0.96
Contribution of mass spectrometry-based proteomics to immunology. Expert Rev Proteomics (2006) 0.90
Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother (2012) 0.90
GVHD suppression by incubation of bone marrow grafts with anti-T-cell globulin: effect in the canine model and application to clinical bone marrow transplantation. Transplant Proc (1979) 0.81
Inducing efficient cross-priming using antigen-coated yeast particles. J Immunother (2008) 0.79
Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. Eur J Immunol (2013) 0.77
Antibody therapy in renal cell carcinoma. World J Urol (2008) 0.77
Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer. Immunol Cell Biol (2006) 0.77
Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol (1995) 0.76
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem (2002) 2.39
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol (2005) 1.08
The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood (2002) 1.03
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother (2012) 1.02
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol (2013) 0.98
Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood (2002) 0.96
The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 0.94
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology (2013) 0.91
Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress Chaperones (2005) 0.89
Multiple synergizing factors contribute to the strength of the CD8+ T cell response against listeriolysin O. Int Immunol (2005) 0.81